Mitsubishi UFJ Asset Management Co. Ltd. Sells 243,230 Shares of Moderna, Inc. $MRNA

Mitsubishi UFJ Asset Management Co. Ltd. cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 36.9% in the second quarter, HoldingsChannel reports. The firm owned 416,020 shares of the company’s stock after selling 243,230 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Moderna were worth $11,478,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. S Bank Fund Management Ltd purchased a new stake in Moderna during the first quarter valued at $25,000. Atlantic Union Bankshares Corp purchased a new position in shares of Moderna in the 2nd quarter worth $26,000. TD Private Client Wealth LLC increased its holdings in shares of Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the last quarter. Whittier Trust Co. purchased a new stake in shares of Moderna during the 2nd quarter valued at about $28,000. Finally, SVB Wealth LLC purchased a new stake in shares of Moderna during the 1st quarter valued at about $28,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on MRNA shares. JPMorgan Chase & Co. dropped their price target on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday, October 23rd. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. UBS Group dropped their target price on Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, October 23rd. Bank of America cut their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday. Finally, Morgan Stanley increased their price target on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $36.14.

Moderna Stock Performance

Moderna stock opened at $26.71 on Thursday. The company has a 50 day moving average price of $25.92 and a 200-day moving average price of $27.11. Moderna, Inc. has a fifty-two week low of $23.04 and a fifty-two week high of $48.92. The company has a market capitalization of $10.44 billion, a PE ratio of -3.31 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.Moderna’s revenue was down 45.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.